CBP/catenin signaling pathway inhibitors and uses thereof

A method of treating a disease or disorder, comprising administering to a patient or a warm-blooded mammal, having a disease or disorder mediated by CREB binding protein (CBP)/β-catenin signaling, a therapeutically effective amount of a compound, or of a composition or pharmaceutical composition comprising same, wherein the disease or disorder is one or more of cancer, neurological conditions, and age-related diminished immune response, and wherein the compound is of formula (Ia):

• or a pharmaceutically acceptable salt thereof, wherein:
• Ra is hydrogen or —CH3;
• Rb is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and which may have one or more substituents selected from a group consisting of halide, cyano, and lower alkyl;
• R is a phenyl group;
• a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C1-4alkylamino, C1-4dialkylamino, halogen, perfluoro C1-4alkyl, C1-4alkyl, C1-3alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups;
• a benzyl group;
• a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C1-4alkylamino, C1-4dialkylamino, halogen, perfluoro C1-4alkyl, C1-3alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group;
• or a bicyclic aryl group, or substituted bicyclic aryl, having 8 to 11 ring members, which may have 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur, where the substituted bicyclic aryl may have one or more substituents independently selected from amino, amidino, guanidino, hydrazino, amidazonyl, C1-4alkylamino, C1-4dialkylamino, halogen, perfluoro C1-4alkyl, C1-3alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group;
• R2 is hydrogen, or —CH3;
• Y is selected from:
• hydrogen, deuterium, or halogen;
• W is hydrogen, phosphate or phosphate salt, an ester of an alkyl acid or of a fatty acid, or X, wherein X is selected from:
• wherein Z is OR4 where R4 is hydrogen or C1-C6 alkyl, or Z is an amino acid or amino acid ester, and n is 1 or 2;
• L is —CH2—, —CF2—, or —C(CH3)2—;
• and
• Q is a 5- or 6-membered nitrogen-containing heteroaryl substituted by 0-2 substituents, selected from:
• wherein A, B, and D are independently selected from O, S, N, or —CH, wherein Z1, Z2 are independently selected from hydrogen, deuterium, halogen, C1-C4 alkyl, —OH, —OC1-C6 alkyl, and
• wherein R1, R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, or C1-C6 alkyl containing one or more-OH, and wherein Z3 is selected from hydrogen, halogen, or a direct-bonded, or —NH-linked, —OC1-C3 alkyl linked, or —NHC1-C3 alkyl linked aryl, heteroaryl, cycloalkyl, heterocycloalkyl, or a nitrogen-bonded cycloalkyl, heterocycloalkyl, or —NHC1-C4 alkyl, —N(C1-C4 alkyl)2, each of which is substituted by 0-4 substituents independently selected from hydrogen, deuterium, halogen, C1-C4 alkyl, C1-C3 haloalkyl, —OH, —OC1-C6 alkyl, —OC1-C6 alkyl-C(O)NH—OH, —NH2, —C(O)NH—C1-C6 alkyl-heteroaryl, —NHC(O)C1-C6 alkyl-C(O)NH—OH, heteroaryl, cycloalkyl, heterocycloalkyl, or a nitrogen-bonded cycloalkyl or heterocycloalkyl, —NHC1-C4 alkyl, or —N(C1-C4 alkyl)2.